| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 10g |
|
||
| Other Sizes |
|
Purity: ≥98%
Idebenone (also known as CV-2619) is a synthetic analog of coenzyme Q10 (CoQ10) and a brain stimulant. Idebenone effectively protects from retinal cell injury after oxidative stress or hypoglycemia, whereas the protection afforded after postincubation of both antioxidants is decreased. Idebenone attenuates delayed retinal cell damage, mediated by chemical ischemia. Idebenone, a centrally active antioxidant used to treat multiinfarct dementia, protects cells from this form of glutamate-induced cytotoxicity in vitro. Idebenone provides significant protection against the neuronal degeneration induced by intrastriatal injection of kainic acid and quisqualic acid, but not the NMDA receptor agonist, quinolinic acid.
| ln Vitro |
Idebenone exists in two distinct oxidative states: reduced idebenone, which is a ubiquinol derivative, and oxidized idebenone, which is a ubiquinone derivative. This molecule has protective activity against neurotoxicity in both in vitro and in vivo models[1]. The oxidized form of idebenone preferentially inhibits the metabolism of cyclooxygenase over lipoxygenase (IC50 ratio lipoxygenase/cyclooxygenase: 3.22)[1]. The oxidized version of idebenone functions similarly to two common anti-inflammatory drugs, piroxicam and indomethacin[1]. For a duration of 24 to 72 hours, idebenone (1–10 μM) had no influence on the viability of SHSY-5Y cells [2]. Idebenone (at 25 μM or greater doses; for 24-72 h) significantly lowers SHSY-5Y cell viability[2]. Idebenone (30 μM) causes the expression of BAX and caspase-3 activity to be upregulated[2].
|
||
|---|---|---|---|
| ln Vivo |
Idebenone (oxidised form) is a chemical with preventive activity against cerebrovascular diseases in vivo, including cerebral ischemia and hypertension-induced vascular lesions[1].
|
||
| Cell Assay |
Cell Viability Assay[2]
Cell Types: The human dopaminergic neuroblastma cell line, SHSY-5Y cells Tested Concentrations: 1, 3, 10, 15, 25, 30, and 90 μM Incubation Duration: 24, 48, and 72 hrs (hours) Experimental Results: Had no apparent detrimental effects on cell viability as indicated by the absence of trypan blue-positive staining in the cells at concentrations of 1, 3, 10 μM. demonstrated some degree of trypan blue-positive staining at 15 μM. demonstrated extensive trypan blue-positive staining at 25 μM and 30 μM. RT-PCR[2] Cell Types: SHSY-5Y cells Tested Concentrations: 10 μM, 30 μM Incubation Duration: 72 hrs (hours) Experimental Results: The total RNA of BAX from SHSY-5Y cells exposed to 10 μM was not different from that of the untreated control cells. The BAX expression in SHSY-5Y cells exposed to 30 μM was Dramatically up-regulated when compared with the untreated control cells and cells exposed to 10 μM. |
||
| Animal Protocol |
|
||
| References |
[1]. G Civenni, et al. Inhibitory effect of the neuroprotective agent idebenone on arachidonic acid metabolism in astrocytes.Eur J Pharmacol. 1999 Apr 9;370(2):161-7.
[2]. Kwok-Keung Tai, et al. Idebenone induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells. Neurotox Res. 2011 Nov;20(4):321-8. |
| Molecular Formula |
C19H30O5
|
|
|---|---|---|
| Molecular Weight |
338.44
|
|
| CAS # |
58186-27-9
|
|
| Related CAS # |
|
|
| SMILES |
O=C1C(CCCCCCCCCCO)=C(C)C(C(OC)=C1OC)=O
|
|
| InChi Key |
JGPMMRGNQUBGND-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C19H30O5/c1-14-15(12-10-8-6-4-5-7-9-11-13-20)17(22)19(24-3)18(23-2)16(14)21/h20H,4-13H2,1-3H3
|
|
| Chemical Name |
2-(10-Hydroxydecyl)-5,6-dimethoxy-3-methyl-p-benzoquinone
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.39 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.39 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.39 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9547 mL | 14.7737 mL | 29.5473 mL | |
| 5 mM | 0.5909 mL | 2.9547 mL | 5.9095 mL | |
| 10 mM | 0.2955 mL | 1.4774 mL | 2.9547 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA